dc.creatorSilva, SD
dc.creatorAgostini, M
dc.creatorNishimoto, IN
dc.creatorColetta, RD
dc.creatorAlves, FA
dc.creatorLopes, MA
dc.creatorKowalski, LP
dc.creatorGraner, E
dc.date2004
dc.dateAUG
dc.date2014-11-18T03:29:56Z
dc.date2015-11-26T17:45:55Z
dc.date2014-11-18T03:29:56Z
dc.date2015-11-26T17:45:55Z
dc.date.accessioned2018-03-29T00:28:23Z
dc.date.available2018-03-29T00:28:23Z
dc.identifierOral Oncology. Pergamon-elsevier Science Ltd, v. 40, n. 7, n. 688, n. 696, 2004.
dc.identifier1368-8375
dc.identifierWOS:000222810000006
dc.identifier10.1016/j.oraloncology.2004.01.004
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/66474
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/66474
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/66474
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1288335
dc.descriptionFatty acid synthase (FAS) is a multifunctional enzyme responsible for the synthesis of saturated fatty acids using acetyl-CoA and malonyl-CoA as substrates. Overexpression of FAS has been reported in several human malignancies and suggested as a potential prognostic factor. ErbB2 (Her-2/neu), a transmembrane tyrosine kinase member of the ErbB receptor family, is known to be overexpressed in a variety of tumors and was recently shown to regulate FAS production in breast epithelial cell lines. Herein we analyzed by immunohistochemistry the expression of FAS, ErbB2, and the proliferation marker Ki-67 in 62 head and neck squamous cell carcinoma (HNSCC) samples. Approximately 78% of the cases were positive for FAS or ErbB2 at the cell membrane and 70% of the tumors that showed a high expression of FAS were also strongly positive for ErbB2 (Fisher's exact test, p = 0.01). The immunolabeling for both FAS and ErbB2 was stronger in histologically well-differentiated lesions. Additionally, Ki-67 expression was significantly associated with a poor prognosis (log-rank test, p = 0.03). Taken together, the results presented here suggest that ErbB2 regulates FAS expression in HNSCC and point out Ki-67 as a useful prognostic marker for these tumors. (C) 2004 Elsevier Ltd. All rights reserved.
dc.description40
dc.description7
dc.description688
dc.description696
dc.languageen
dc.publisherPergamon-elsevier Science Ltd
dc.publisherOxford
dc.publisherInglaterra
dc.relationOral Oncology
dc.relationOral Oncol.
dc.rightsfechado
dc.rightshttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.sourceWeb of Science
dc.subjectoral squamous cell carcinoma
dc.subjectfatty acid synthase
dc.subjectErbB2
dc.subjectHer-2/neu
dc.subjectKi-67
dc.subjectimmuno-histochemistry
dc.subjectsurvival analysis
dc.subjectprognostic marker
dc.subjectoral cancer
dc.subjectEpidermal-growth-factor
dc.subjectHuman Prostate-cancer
dc.subjectOvarian Neoplasms
dc.subjectGene-expression
dc.subjectNeu Oncogene
dc.subjectProtein
dc.subjectReceptors
dc.subjectProgression
dc.subjectC-erbb-2
dc.subjectSurvival
dc.titleExpression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma. A clinicopathological study
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución